lar events and diabetic complications. After 100,000 individuals are assigned baseline characteristics by sampling UK data, their baseline risks are predicted and they enter a main module where these are applied. Periodic updating takes place at doctors' visits and other events, such as premature treatment discontinuation and complications. Resource use, costs and utilities were obtained from UK databases. All outcomes are discounted at 3.5%/year. RESULTS: After one year treatment, patients on rimonabant plus diet and exercise lose more than three times the weight and show greater improvements in other cardiometabolic risk factors than patients on diet and exercise alone. With diet and exercise, 633 cardiovascular and 411 microvascular events are predicted to occur per 1000 patients, over 60 years. Lifetime costs average ≤5692/patient. One year of rimonabant reduces cardiovascular and microvascular events by 18 and 10, respectively, with a corresponding reduction in complication costs. Discounted life expectancy increases by 40.2 years, and QALYs by 113.8. Extending treatment to 5 years increases life years and QALYs gained by a further 38 and 48%, respectively. Extensive sensitivity analyses, including varying the cost of treatment with rimonabant, indicate that rimonabant is cost-effective over a wide range of inputs. CONCLUSIONS: Rimonabant for the treatment of overweight or obese patients with or without comorbidities in the UK should be associated with acceptable cost-effectiveness ratios under a wide range of assumptions.
ES6 ENTRY AND PRICE RESPONSE IN MARKETS WITHOUT PATENT PROTECTION:THE CASE OF PHARMACEUTICALS IN ARGENTINA
Maceira DA Center for the Study of the State and Society, Ciudad Autónoma de Buenos Aires, Argentina OBJECTIVES: The goal of this paper is to test the leaderfollower model in the Argentinean pharmaceutical markets where patent protection does not apply allowing immediate entry. METHODS: It was used a leader-follower model where followers take leader prices to decide their own ones and the leader strategically incorporates followers' behavior in its decision. Two different groups of followers are studied separating the main three from the rest of the market competitors. The data used in this study is based in information published by Pharmaceutical Markets Argentina (PMA) complemented with indicators of needs and chronicity, obtained through interviews with physicians and pharmacologists, as well as the list of chemical entities used in the production of each product, and the nationality of manufactures. RESULTS: From the group of 88 therapeutic classes selected, 56 classes kept the same leader during the period 1988-1995, although just in nine of those cases the first entrant remains as market leader. The cases where market leader remains the same during the sample period but they were not necessarily the first entrants are defined as loose leadership markets, while cases of strict leadership are those where first entrants remained as market leaders during the sample period. CONCLUSIONS: The leader-follower hypothesis is checked and supported by the data, mirroring the results obtained under a patent regime. In addition, the lack of patents also raises the question of difference in behavior among followers. Therefore, two differentiated groups of followers are studied separating the main three from the rest of the market competitors.
ES7 DIRECT MEDICAL COSTS OF STROKE ACCORDING TO HANDICAP LEVELS AFTER 12 AND 18 MONTHS
Bouchez M 1 , Jasso Mosqueda G 1 , Spieler JF 2 , De Pouvourville G 3 , Chicoye A 1 , Amarenco P 2 1 Aremis-aegisnet, Neuilly sur Seine, France, 2 Service de Neurologie Hôpital Bichat, Paris, France, 3 Gustave Roussy Institute, Villejuif, France Stroke is the leading cause of long term disability worldwide and a frequent cause of hospital admissions. Considering the population aging, stroke is a growing health problem, and is increasingly more costly to manage. Financial burden is caused by the outcomes of acute stroke and its impact on a variety of health care resources. OBJECTIVES: To provide referential of health care resources and direct medical costs of post-acute management of stroke per handicap levels within the new French National Health System context. METHODS: Information provided by ECIC study on post-acute care delivered to 434 consecutive patients with stroke was considered to update data on the cost of stroke in France. Data on handicap levels assessed 10 days after stroke onset (Rankin scale), medication, rehabilitation, nursing care and ambulatory costs were obtained over 12 and 18 months after the initial acute hospital discharge. With a NHS perspective, only direct medical costs were considered. RESULTS: The mean direct medical cost of stroke in France, all handicap levels considered, is estimated at €15,644 and €17,699 over the first 12 and 18 month-periods respectively. At 18 months this cost increases from €8624.5 for patient with Rankin 1 to €39,010.5 for patients with Rankin 5. For patients with lower handicap (Rankin 1-3) hospitalisation for the acute management of stroke is the main driver of costs, whereas for patients with higher Rankin rehabilitation accounts for 70% of the total direct medical costs. CONCLUSION: Costs increase by five fold between the lowest and the highest handicap level. Whatever the Rankin considered, costs incurred during the first year represent almost 90% of cost at 18 months. New therapeutic advances reducing post-stroke consequences could have a major impact on health care expenditures.
ES8 TREATMENT COSTS OF DIFFERENT PHASES IN BREAST CANCER (BC) IN HUNGARY
Muszbek N 1 , Benedict A 2 , Horvath K 3 1 UnitedBiosource Corporation, London, UK, 2 UnitedBiosource Corporation, Budapest, Hungary, 3 Astra Zeneca Hungary, Torokbalint, Hungary OBJECTIVES: While breast cancer has a high incidence worldwide, there is limited data on treatment costs to help decisionmakers establish the cost-effectiveness of new treatments. This study's objective was to determine treatment costs of BC stages for postmenopausal BC patients in Hungary. METHODS: BCspecific resource use items were collected retrospectively on three cohorts: early breast cancer (EBC), local regional recurrence (LRR) and metastatic breast cancer (MBC) patients. Data was obtained from National Health Insurance Fund claims databases on inpatients, outpatients and pharmaceuticals. Cohorts were determined using ICD, WHO, ATC, TNM and procedure codes. Age > 55 served as proxy for postmenopausal status. The first 100 relevant patients at each stage entering the Oncology Report database in 2003 were included and followed for 1 year. Average annual patient costs with 95% confidence intervals (95%CI) were established using Hungarian national fee schedules and reported in euros. RESULTS: The final cohort included 87 patients with incident EBC, 79 patients with LRR, and 99 patients receiving active or palliative care for MBC. The frequency of diagnostic and surgical procedures, consultant visits and prescriptions were summarized in natural units. Average (95%CI) outpatient, inpatient and drug cost/patient for EBC patients were estimated to be €1000 (780-1260), €1060 (800-1300) and €2470 (2100-2840) respectively. For LRR patients the corresponding figures were €274 (214-330), €2056 (1470-2600) and €2160 (1600-2700). In MBC values averaged €260 (210-310), €1150 (850-1550) and €3470 (2800-4150) respectively. Drug costs represented 23%, 40% and 29% of total treatment costs/patient in EBC, LRR and MBC. Costs were highest in MBC. CONCLUSIONS: Inpatient costs represent the highest proportion of costs, followed closely by drug costs, possibly due to relatively low labour costs in Central Europe. These estimates and underlying treatment patterns will be useful in establishing the cost-effectiveness of new BC treatments in Hungary and potentially in the region.
OSTEOPOROSIS & ARTHRITIS OA1 QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS TREATED WITH COMBINATION VS. SINGLE DRUG THERAPY-RESULTS FROM FIN-RACO TRIAL
Hahl J 1 , Bergius S 1 , Sintonen H 2 , Hannonen P 3 , Korpela M 4 , Leirisalo-Repo M 5 , Hakala M 6 , Möttönen T 7 1 GlaxoSmithKline Oy, Espoo, Finland, 2 University of Helsinki, Helsinki, Finland, 3 Jyväskylä Central Hospital, Jyväskylä, Finland, 4 Tampere University Hospital, Tampere, Finland, 5 Helsinki University Central Hospital, Helsinki, Finland, 6 Rheumatism Foundation Hospital, Heinola, Finland, 7 Turku University and Turku University Central Hospital, Paimio, Finland The Finnish rheumatoid arthritis (RA) combination therapy (FIN-RACo) trial has shown better efficacy of three diseasemodifying antirheumatic drugs (DMARD) (sulphasalazine, methotrexate, hydroxychloroquine) and prednisolone compared to treatment with a single DMARD with or without prednisolone in early RA. Results from FIN-RACo trial show that early aggressive combination therapy (COMBI) translated into more remissions and less peripheral joint damage, cervical spine subluxations, and work disability than therapy with a single DMARD (SINGLE). OBJECTIVES: Estimate health-related quality of life (HRQoL) effects of COMBI vs. SINGLE in early RA. METHODS: A total of 195 patients with early RA were randomised to COMBI (n = 97) or SINGLE (n = 98) for 2 years. Thereafter drug treatment became unrestricted. HRQoL was measured using the 15D instrument. The 15D score of an additional control sample was used as an estimate of baseline HRQoL in early RA. RESULTS: The baseline 15D score was 0.856 (95% CI 0.835-0.877; n = 49). The respective five and 10-11 years 15D scores of COMBI were significantly better than the baseline score (0.929; n = 28, p = 0.000 and 0.901; n = 39, p = 0.002), in contrast to the corresponding scores of SINGLE (0.880; n = 34, p = 0.078 and 0.858; n = 30, p = 0.900). The differences between the COMBI and SINGLE scores at 5 and 10-11 years reached statistical significance (p = 0.017 and 0.046), too. CONCLUSION: Early aggressive treatment with combination of DMARDs is effective also from the viewpoint of HRQoL. The effect sustains at least up to 10-11 years.
OA2 SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES
Lyssy AE 1 , Schaefer M 2 1 Institut für Klinische Pharmakologie Medizinische Fakultät der Humboldt-Universität/Charité, Berlin, Germany, 2 Institut für Klinische Pharmakologie, Berlin, Germany OBJECTIVES: To evaluate whether it is accepted that community pharmacies identify elderly people which are at risk for osteoporosis and furthermore evaluate the effectiveness of community pharmacies to motivate identified patients at risk for osteoporosis to consult a physician for further diagnosis and treatment. METHODS: Prospective multi-centre pre-post evaluation in 20 community pharmacies in Southern Germany including 765 patients. The screening for risk for osteoporosis was based on an adapted osteoporosis risk-questionnaire of the "Kuratorium Knochengesundheit e.V.-German Self-Help-Group". Patients with identified risk were consulted with regard to the disease osteoporosis and recommended to see a physician for further diagnosis. A maximum of 2 follow-up contacts were undertaken to receive information whether or not a physician was seen by the patient. RESULTS: Out of 765 patients, which were interviewed using the osteoporosis risk-questionnaire 53% were identified being at risk and thus were requested to contact their physician. 66% of these patients did respond to the recommendation by the community pharmacy and did see a physician for consultation and further diagnosis of osteoporosis. As a result, an anti-osteoporotic pharmacotherapy was initiated in 33% of those patients who saw a physician. Overall, 57% of patients indicated their satisfaction with the service provided by the pharmacy and 64% agreed that a community pharmacy is an appropriate place to offer screening for osteoporosis. CON-CLUSION: Community pharmacies are easy to access by elderly people and a screening for osteoporosis using an osteoporosis screening risk-questionnaire was accepted by the majority of patients.
OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

